This article does not advertise a prescription-only medicine or imply that a named treatment is available from the clinic. Treatment decisions require an individual medical consultation.
What side effects are common?
Gastrointestinal effects such as nausea, vomiting, diarrhoea, constipation, abdominal discomfort and reduced appetite are commonly reported with incretin-based medicines.
Severity matters. Persistent vomiting or diarrhoea can lead to dehydration and may affect kidney function or the safe use of other medicines.
Which symptoms need urgent medical advice?
Severe persistent abdominal pain, particularly when it radiates to the back or occurs with vomiting, needs urgent assessment because pancreatitis is one possible cause.
- Persistent vomiting or inability to keep fluids down
- Symptoms of severe dehydration
- A severe allergic reaction
- Sudden visual disturbance
- Any symptom that feels severe, rapidly worsening or requires emergency assessment
What should be discussed before surgery or pregnancy?
Tell the surgical and anaesthetic team about current medicines, and discuss pregnancy, plans for pregnancy, breastfeeding and contraception with the prescriber.
Some medicines affect stomach emptying and may alter peri-operative planning. Product-specific contraception advice can differ, so current UK information should be checked rather than assumed.
How can suspected adverse reactions be reported?
Patients and professionals can report suspected medicine adverse reactions through the MHRA Yellow Card scheme.
Counterfeit or illegally supplied products may contain the wrong ingredient or dose and may not meet expected quality or storage standards.
Frequently asked questions
No. Mild symptoms may settle, but persistent or severe symptoms can affect hydration, nutrition and safety and should be reviewed.
No. The objective is acceptable clinical benefit with tolerable adverse effects, within the licence and individual prescribing judgement.
References
- Medicines and Healthcare products Regulatory Agency. GLP-1 receptor agonists: reminder of potential side effects and misuse. 24 October 2024. UK drug-safety communication. Accessed 12 June 2026.
- Medicines and Healthcare products Regulatory Agency. Yellow Card: report a problem with a medicine or medical device. Current service. UK pharmacovigilance service. Accessed 12 June 2026.
- National Institute for Health and Care Excellence. Overweight and obesity management (NG246). 8 January 2026. UK clinical guideline. Accessed 12 June 2026.